Gary Steven Goldman
“ Dr. Goldman has served as a reviewer for the Journal of the American Medical Association (JAMA), Vaccine, AJMC, ERV, ERD, JEADV,and British Medical Journal (BMJ). He is included on the Editorial Board of Research and Reviews in BioSciences. ”
In 1980, as vice-president of Systems Development of Cascade Graphics Development, he developed the first microcomputer-based computer-aided drafting (CAD) system (prior to the well known AutoCad product.
Dr. Goldman served for eight years (from January1995 through October of 2002) as Research Analyst for the Varicella Active Surveillance Project in Antelope Valley, in a cooperative project with the Centers for Disease Control and Prevention (CDC, Atlanta, GA).
Dr. Goldman has served as a reviewer many peer-reveiwed journals.
Recent Medical Publications, Abstracts, etc.
 The impact of vaccination on varicella incidence, conditional on school attendance and temperature, in Antelope Valley, CA. Goldman GS, Glasser JW, Maupin TJ, Peterson CL, Mascola L, Chen RT, and Seward, JF. Presentation by J.W. Glasser at 16th International Conference on Pharmacoepidemiology (ICPE); Barcelona, Spain; August 22, 2000; Pharmacoepidemiology and Drug Safety; 9(Suppl 1):S67.
 Varicella active surveillance: use of capture-recapture methods to assess completion of surveillance data. Peterson CL, Maupin T, Goldman G, Mascola L. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 28 - October 1, 1997, Toronto, Canada; Abstract H-111, page 233.
 Decline in varicella incidence and hospitalizations in sentinel surveillance areas in the United States, 1995-2000. Seward J, Watson B, Peterson C, Mascola L, Pelosi J, Zhang J, Jumaan A, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M. The 4th International Conference on VZV, March 3-5, 2001, Oral Presentation, La Jolla, California. VZV Research Foundation in partnership with Columbia University College of Physicians and Surgeons.
 Breakthrough varicella cases since vaccine licensure in the Varicella Active Surveillance Project. April 2001 Supplement of Pediatric Research, Presented April 28-May 1, 2001 Pediatric Academic Societies Meeting, Baltimore, Maryland. Galil K, Watson B, Peterson C, Mascola L, Pelosi J, Seward J, Zhang J5, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M.
 Knowledge, attitudes, and practices of healthcare providers regarding varicella vaccination in sentinel surveillance area, 1996, 1997, and 1999. Maupin T, Goldman G, Peterson C, Mascola L, Seward J. Poster Session, April 28-May 1 2001, Pediatric Academic Society Annual Meeting, Baltimore, Maryland.
 Varicella Epidemiology: six years of active surveillance data following implementation of the varicella vaccination program. Peterson C, Mascola L, Maupin T, Goldman G, Seward J, Presented at the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 943, October 25-28, 2001; San Francisco, California.
 Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Xhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. JAMA 2002; 287(5):606–11.
 Second varicella infections: are they more common than previously thought? Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Pediatrics. 2002 Jun;109(6):1068–73.
 Varicella susceptibility among adolescents in an active surveillance site. Maupin T, Goldman G, Peterson C, Mascola L, Seward J, Jumaan A, 36th National Immunization Conference of the CDC, May 1, 2002, Denver, Colorado.
 Varicella susceptibility and incidence of herpes-zoster among children and adolescents in a community under active surveillance. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4238–42.
 Incidence of herpes-zoster among children and adolescents in a community with moderate varicella vaccination coverage. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4243–9.
 Using capture-recapture methods to assess varicella incidence in a community under active surveillance. Goldman G. Vaccine, 2003 Oct 1; 21(27-30):4250–55.
 Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Goldman G. Vaccine, 2005 May; 23(25):3349–55.
 An investigation of the association between MMR vaccination and autism in Denmark. Goldman G, Yazbak EF, Journal of Association of American Physicians and Surgeons, Fall 2004; 9(3):70–5.
 Response to Letter to Editor by Jumaan: Goldman’s role in the Varicella Active Surveillance Project. Goldman GS. Vaccine, 2004 Sep 3; 22(25-26):3232–6. (doi:10.1016/j.vaccine.2004.07.001)
 Universal varicella vaccination: Efficacy trends and effect on herpes-zoster. Goldman GS. International Journal of Toxicology, 2005 July-Aug.;24(4):205–13.
 The Case against Universal Varicella Vaccination. [Commentary] Goldman GS. International Journal of Toxicology, 2006 Sept.-Oct.,25(5):313–17.